VERU INC. Operating Lease, Right-of-Use Asset, Amortization Expense
VERU INC. (VERU) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $403.83 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-10
- VERU INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $137.16K, a 7.78% increase year-over-year.
- VERU INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $134.57K, a 7.70% increase year-over-year.
- VERU INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $132.09K, a 33.81% decline year-over-year.
- VERU INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $129.66K, a 33.52% decline year-over-year.
- VERU INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $581.45K, a 24.56% decline from fiscal 2024.
- VERU INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $770.70K, a 3.97% increase from fiscal 2023.
- VERU INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $741.26K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $137.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-10 | $271.73K derived: sum of 2 quarters · filed 2026-08-10 | $403.83K 10-Q · filed 2026-08-10 | $533.49K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $134.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $266.67K 10-Q · filed 2026-05-13 | $396.32K derived: sum of 3 quarters · filed 2026-05-13 | $523.59K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $132.09K 10-Q · filed 2026-02-11 | $261.75K derived: sum of 2 quarters · filed 2026-02-11 | $389.02K derived: sum of 3 quarters · filed 2026-08-10 | $513.97K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-09-30 | $129.66K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | $256.92K derived: sum of 2 quarters · filed 2026-08-10 | $381.87K derived: sum of 3 quarters · filed 2026-08-10 | $581.45K 10-K · filed 2025-12-17 |
| 2025-06-30 | $127.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-10 | $252.22K derived: sum of 2 quarters · filed 2026-08-10 | $451.80K 10-Q · filed 2026-08-10 | $646.83K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $124.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13 | $324.53K 10-Q · filed 2026-05-13 | $519.57K derived: sum of 3 quarters · filed 2026-05-13 | $710.17K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $199.58K 10-Q · filed 2026-02-11 | $394.62K derived: sum of 2 quarters · filed 2026-02-11 | $585.22K derived: sum of 3 quarters · filed 2026-02-11 | $771.53K derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $195.04K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | $385.64K derived: sum of 2 quarters · filed 2025-12-17 | $571.95K derived: sum of 3 quarters · filed 2025-12-17 | $770.70K 10-K · filed 2025-12-17 |
| 2024-06-30 | $190.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $376.91K derived: sum of 2 quarters · filed 2025-08-12 | $575.66K 10-Q · filed 2025-08-12 | $760.44K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $186.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-08 | $385.06K 10-Q · filed 2025-05-08 | $569.84K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $198.75K 10-Q · filed 2025-02-13 | $383.53K derived: sum of 2 quarters · filed 2025-02-13 | ||
| 2023-09-30 | $184.78K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $741.26K 10-K · filed 2024-12-16 | ||
| 2023-06-30 | $556.48K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |